Enhanced inhibition of tumor cell proliferation using a combination of two monoclonal antibodies to the human transferrin receptor
US5667781A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Sep 30, 1991 |
| Grant date | Sep 16, 1997 |
| Priority date | — |
| Expiry date | Sep 30, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Combinations of monoclonal antibodies which are highly effective for inhibiting cell growth and methods for inhibiting cell growth employing novel combinations of monoclonal antibodies are disclosed. The antibodies employed are capable of binding to the human transferrin receptor glycoprotein and, in combination, usually exhibit a substantially greater inhibition of cell growth than either of the antibodies individually when administered in comparable amounts, e.g. at saturation conditions. In preferred combinations, at least one member of the combination is individually highly effective to inhibit cell growth and at least one other member of the combination is individually substantially ineffective to inhibit cell growth. Combinations are selected based upon an in vitro screening test using CCRF-CEM cells which express the human Tf receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.